Candel Therapeutics, Inc. (NASDAQ: CADL) shares are are trading lower Thursday after the company released final survival data from its phase 2a clinical trial of CAN-2409.
Candel Therapeutics Shares Are Down Today: What’s Going On?
Where Today's News Shapes Tomorrow
